Directors

Chairman and CEO

Hardy TS Kagimoto, MD

Hardy TS Kagimoto founded a biotech company after working at Kyushu University Hospital, where he developed an adjuvant to stain containing BBG250 (which had been invented by Kyushu University in Japan). The product was launched in Europe after a self-conducted Phase III study in India and the US, and is now established de-facto-standard status in ophthalmic surgery.
He then founded HEALIOS K.K. in 2011 to realize his driving objective, the development of a therapy for age-related macular degeneration.

Executive Officer